Clinical Trial Update: Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Endostar plus SBRT and Envafolimab for advanced gastrointestinal tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neoplasms

Drugs mentioned

• Endostar (recombinant human endostatin)
• Envafolimab (envafolimab)
• SBRT (stereotactic body radiotherapy)

Snippet

Sponsor: Nanjing First Hospital, Nanjing Medical University | Conditions: Gastrointestinal Neoplasms | Phase 2 | Status: UNKNOWN